Diffuse Large B-cell Lymphoma: Clinical Trials

4 trials for Diffuse Large B-cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 unknown. 4 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 14Unknown 4
Phase 21Unknown 1

Follow Diffuse Large B-cell Lymphoma: new trials by email Literature Review of Diffuse Large B-cell Lymphoma trials Research Report on Diffuse Large B-cell Lymphoma

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma
CD19-7×19 CAR-T plus PD1 monoclonal antibody - Diffuse Large B-cell Lymphoma
Phase 1UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine242020-06-182023-02-06
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
CTA101 - Diffuse Large B-cell Lymphoma
Phase 1UnknownThe First Affiliated Hospital with Nanjing Medical University92019-12-012019-10-31
Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
Human CD19 targeted T Cells Injection - CD19-positive, Diffuse Large B-cell Lymphoma
Phase 1UnknownHrain Biotechnology Co., Ltd.182018-11-132021-08-31
Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin Lymphoma
Cyclophosphamide, Cytarabine, Doxorubicin Hydrochloride - Adult Burkitt Lymphoma, B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Burkitt Lymphoma
Phase 1 / Phase 2UnknownNorthwestern University382015-10-282022-02-21

Narrower conditions

Lymphoma, Large B-Cell, Diffuse (4)  ·  Burkitt Lymphoma (1)  ·  Lymphoma, B-Cell (1)  ·  Lymphoma, Follicular (1)  ·  Plasmablastic Lymphoma (1)

Broader conditions

Hemic and Lymphatic Diseases (4)  ·  Immune System Diseases (4)  ·  Immunoproliferative Disorders (4)  ·  Lymphatic Diseases (4)  ·  Lymphoma (4)  ·  Lymphoma, Non-Hodgkin (4)  ·  Lymphoproliferative Disorders (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Lymphoma, B-Cell (3)  ·  DNA Virus Infections (1)  ·  Epstein-Barr Virus Infections (1)  ·  Herpesviridae Infections (1)  ·  Infections (1)  ·  Tumor Virus Infections (1)

Interventions

Cyclophosphamide (1)  ·  Cytarabine (1)  ·  Doxorubicin (1)  ·  Etoposide (1)  ·  Hydrocortisone (1)  ·  Methotrexate (1)  ·  Prednisone (1)  ·  Rituximab (1)  ·  Vincristine (1)  ·  deltacortene (1)  ·  ixazomib (1)  ·  merphos (1)  ·  prednylidene (1)

Sponsors

Hrain Biotechnology Co., Ltd. (1)  ·  Northwestern University (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  The First Affiliated Hospital with Nanjing Medical University (1)

Countries

China (3)  ·  United States (1)

Top investigators

Barbara Pro, MD (1)  ·  Wenbin Qian, MD, PhD (1)

Results publications

PMID 34515338, PMID 36536403, PMID 38237077

NIH funding

P30CA060553 (1)